UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 30,188 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 17.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 140,371 shares of the company’s stock after selling 30,188 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Vir Biotechnology were worth $1,051,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in VIR. Charles Schwab Investment Management Inc. grew its position in Vir Biotechnology by 13.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock worth $8,496,000 after buying an additional 136,087 shares in the last quarter. Affinity Asset Advisors LLC bought a new stake in Vir Biotechnology during the second quarter worth $1,780,000. Point72 Hong Kong Ltd boosted its holdings in shares of Vir Biotechnology by 180.6% in the 2nd quarter. Point72 Hong Kong Ltd now owns 19,572 shares of the company’s stock valued at $174,000 after purchasing an additional 12,598 shares in the last quarter. Millennium Management LLC increased its stake in shares of Vir Biotechnology by 94.6% in the 2nd quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock valued at $11,108,000 after purchasing an additional 606,804 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Vir Biotechnology during the 3rd quarter worth $191,000. 65.32% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of Vir Biotechnology in a research note on Wednesday, November 20th. HC Wainwright reiterated a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Finally, Barclays decreased their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.40.

Vir Biotechnology Stock Down 2.6 %

Shares of VIR stock opened at $7.16 on Thursday. The company has a market cap of $986.08 million, a price-to-earnings ratio of -1.83 and a beta of 0.49. Vir Biotechnology, Inc. has a 52 week low of $6.56 and a 52 week high of $13.09. The firm has a 50 day moving average of $8.03 and a 200-day moving average of $8.58.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $2.38 million during the quarter, compared to the consensus estimate of $5.54 million. During the same quarter in the previous year, the company posted ($1.22) EPS. The firm’s revenue was down 9.8% on a year-over-year basis. Analysts anticipate that Vir Biotechnology, Inc. will post -3.36 earnings per share for the current year.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).